A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

This is a dose finding study to evaluate the safety and determine the maximum tolerated dose of carfilzomib in patients with previously treated systemic light-chain amyloidosis. The study will also explore the efficacy of carfilzomib in both proteasome inhibitor-naive and proteasome inhibitor-exposed patients including hematologic response, organ response, progression free survival, and time to next therapy.

Principal Investigator


Primary Contact:
Ying Hao
(650) 723-0646